Zobrazeno 1 - 10
of 1 218
pro vyhledávání: ''
Autor:
Isamu Okamoto, Tatsuo Ohira, Nobuyuki Yamamoto, Hidehito Horinouchi, Toyoaki Hida, Shinji Atagi, Tatsuro Fukuhara, Miyako Satouchi, Kazuma Kishi, Shunichi Sugawara, Shi Rong Han, Hideo Saka, Victoria Ebiana, Katsuyuki Hotta, Keisuke Aoe, Kazuhiko Nakagawa, Hiroshi Sakai, Hiroaki Okamoto, Kazuo Noguchi, Kaname Nosaki, Atsushi Horiike, Shigeki Umemura, Toshiaki Takahashi, Takayasu Kurata, Nobuyuki Katakami, Akimasa Sekine
Publikováno v:
Cancer Science
Cancer Sci
Cancer Sci
This prespecified subanalysis of the global, randomized controlled phase III KEYNOTE‐024 study of pembrolizumab vs chemotherapy in previously untreated metastatic non‐small‐cell lung cancer without EGFR/ALK alterations and a programmed death li
Autor:
Hoa H.N. Pham, Junya Fukuoka, Qi Wang, Xingzhi Song, Ming Chen, Lauren Averett Byers, Lixia Diao, Won-Chul Lee, Yanhua Tian, Julie George, Shawna M Hubert, Bo Zhu, Xiao Hu, Ying Jin, Nicholas McGranahan, Chang-Jiun Wu, J. Jack Lee, Jing Wang, Carmen Behrens, Jianjun Zhang, Alexandre Reuben, Xin Hu, Jun Li, Roman K. Thomas, Latasha Little, Ignacio I. Wistuba, Junya Fujimoto, Jia Wu, Jiexin Zhang, Edwin R. Parra, Xiuning Le, John V. Heymach, Curtis Gumbs, Robert J. Cardnell, Bonnie S. Glisson, Meijuan Wu, Yamei Chen, Chao Cheng, William N. William, Don L. Gibbons, Runzhe Chen, Chi-Wan Chow, P. Andrew Futreal, Jianhua Zhang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Nature Communications
Nature Communications
Small-cell lung cancer (SCLC) is speculated to harbor complex genomic intratumor heterogeneity (ITH) associated with high recurrence rate and suboptimal response to immunotherapy. Here, using multi-region whole exome/T cell receptor (TCR) sequencing
Autor:
Yuan Wu, Chester Kao, Tian Zhang, Neal Ready, Michael B. Datto, Eric Powers, Jeffrey M. Clarke, John H. Strickler, Michelle F. Green
Publikováno v:
Clinical Lung Cancer. 22:500-509
Introduction A high tumor mutational burden (TMB) (≥10 mut/Mb) has been associated with improved clinical benefit in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI) and is a tumor agnostic indication for pembroliz
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 17, Pp 5794-5808 (2021)
Cancer Medicine, Vol 10, Iss 17, Pp 5794-5808 (2021)
Purpose/Objectives Data are conflicting on the effects of time interval from neoadjuvant chemoradiation (NCRT) to surgery for locally advanced non‐small‐cell lung cancer (LA‐NSCLC). This study investigated the impact of surgical timing after NC
Autor:
Shangkun Yuan, Renfang Chen, Zhehao Xiao, Xiaoying Qian, Fen Liu, Yong Wang, Yong Li, Qian Wang, Chen Fang, Biqi Fu, Xiaotong Qiu, Xinwei Zhang
Publikováno v:
Aging (Albany NY)
Neutrophil extracellular traps (NETs) are closely related to cancer progression. NETs-related lncRNAs play crucial roles in non-small-cell lung cancer (NSCLC) but there have been no systematic studies regarding NETs-related long noncoding RNA (lncRNA
Autor:
Yoshihiro Komohara, Toshiyuki Shima, Masayuki Shimoda, Remi Mito, Yusuke Shinchi, Koei Ikeda, Makoto Suzuki, Takuro Sakagami, Eri Matsubara, Yae Kanai, Yukio Fujiwara
Publikováno v:
Pathology International. 71:666-673
CD163 is one of the scavenger receptors expressed on macrophages. However, several immunohistochemical studies have demonstrated that CD163 is also detected on cancer cells, and is associated with a poor prognosis. In the present study, we detected C
Autor:
Saad Sheikh, Sujay Datta, Tithi Biswas, Charulata Jindal, Mitchell Machtay, Tarun Podder, Afshin Dowlati, Asoke Dey, Jimmy T. Efird
Publikováno v:
Future Oncology. 17:2713-2724
The role of prophylactic cranial irradiation (PCI) and thoracic radiation therapy (TRT) in extensive-stage small cell lung cancer remains controversial. The authors examined the National Cancer Database and identified patients with extensive-stage sm
Publikováno v:
Anti-Cancer Drugs. 32:882-885
Erlotinib is a tyrosine kinase inhibitor that inhibits epidermal growth factor receptor. It is being used for metastatic non-small cell lung cancer patients (NSCLC). Repurposing noncancer drugs for cancer treatment is a current issue and it has many
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 10, Pp 3197-3204 (2021)
Cancer Medicine, Vol 10, Iss 10, Pp 3197-3204 (2021)
Purpose This study investigated the clinical utility of next‐generation sequencing (NGS) for detection of genetic alterations and its implications on treatment of lung adenocarcinoma in real‐world practice. Patients and Methods Data were reviewed
Autor:
Noboru Oriuchi, Ryohei Yamamoto, Yukitoshi Satoh, Akihiro Ichikawa, Satoshi Shiozawa, Nobuhiro Nishizawa, Hideki Endoh
Publikováno v:
Clinical Lung Cancer. 22:218-224
Introduction 2-[18F] Fluoro- d -deoxyglucose (FDG) positron emission tomography (PET) is a relevant diagnostic procedure for staging lung cancer. However, accurate evaluation of lymph node metastases by PET is controversial because of false-positive